Multitarget-directed ligands (MTDLs) are considered a promising therapeutic strategy to address the multifactorial nature of Alzheimer's disease (AD). Novel MTDLs have been designed as inhibitors of human acetylcholinesterases/butyrylcholinesterases, monoamine oxidase A/B, and glycogen synthase kinase 3β and as calcium channel antagonists via the Biginelli multicomponent reaction. Among these MTDLs, (±)-BIGI-3h was identified as a promising new hit compound showing in vitro balanced activities toward the aforementioned recognized AD targets. Additional in vitro studies demonstrated antioxidant effects and brain penetration, along with the ability to inhibit the aggregation of both τ protein and β-amyloid peptide. The in vivo studies have shown that (±)-BIGI-3h (10 mg/kg intraperitoneally) significantly reduces scopolamine-induced cognitive deficits.

(±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease / Ismaili L.; Monnin J.; Etievant A.; Arribas R.L.; Viejo L.; Refouvelet B.; Soukup O.; Janockova J.; Hepnarova V.; Korabecny J.; Kucera T.; Jun D.; Andrys R.; Musilek K.; Baguet A.; Garcia-Frutos E.M.; De Simone A.; Andrisano V.; Bartolini M.; De Los Rios C.; Marco-Contelles J.; Haffen E.. - In: ACS CHEMICAL NEUROSCIENCE. - ISSN 1948-7193. - ELETTRONICO. - 12:8(2021), pp. 1328-1342. [10.1021/acschemneuro.0c00803]

(±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease

De Simone A.;Andrisano V.;Bartolini M.;
2021

Abstract

Multitarget-directed ligands (MTDLs) are considered a promising therapeutic strategy to address the multifactorial nature of Alzheimer's disease (AD). Novel MTDLs have been designed as inhibitors of human acetylcholinesterases/butyrylcholinesterases, monoamine oxidase A/B, and glycogen synthase kinase 3β and as calcium channel antagonists via the Biginelli multicomponent reaction. Among these MTDLs, (±)-BIGI-3h was identified as a promising new hit compound showing in vitro balanced activities toward the aforementioned recognized AD targets. Additional in vitro studies demonstrated antioxidant effects and brain penetration, along with the ability to inhibit the aggregation of both τ protein and β-amyloid peptide. The in vivo studies have shown that (±)-BIGI-3h (10 mg/kg intraperitoneally) significantly reduces scopolamine-induced cognitive deficits.
2021
(±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease / Ismaili L.; Monnin J.; Etievant A.; Arribas R.L.; Viejo L.; Refouvelet B.; Soukup O.; Janockova J.; Hepnarova V.; Korabecny J.; Kucera T.; Jun D.; Andrys R.; Musilek K.; Baguet A.; Garcia-Frutos E.M.; De Simone A.; Andrisano V.; Bartolini M.; De Los Rios C.; Marco-Contelles J.; Haffen E.. - In: ACS CHEMICAL NEUROSCIENCE. - ISSN 1948-7193. - ELETTRONICO. - 12:8(2021), pp. 1328-1342. [10.1021/acschemneuro.0c00803]
Ismaili L.; Monnin J.; Etievant A.; Arribas R.L.; Viejo L.; Refouvelet B.; Soukup O.; Janockova J.; Hepnarova V.; Korabecny J.; Kucera T.; Jun D.; Andrys R.; Musilek K.; Baguet A.; Garcia-Frutos E.M.; De Simone A.; Andrisano V.; Bartolini M.; De Los Rios C.; Marco-Contelles J.; Haffen E.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/855822
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact